These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38692445)

  • 21. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J; Ezekowitz JA; Collins SP; Givertz MM; Teerlink JR; Walsh MN; Albert NM; Westlake Canary CA; Carson PE; Colvin-Adams M; Fang JC; Hernandez AF; Hershberger RE; Katz SD; Rogers JG; Spertus JA; Stevenson WG; Sweitzer NK; Tang WH; Stough WG; Starling RC
    J Card Fail; 2012 Apr; 18(4):265-81. PubMed ID: 22464767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Initiation of eplerenone or spironolactone, treatment adherence, and associated outcomes in patients with new-onset heart failure with reduced ejection fraction: a nationwide cohort study.
    Larsson JE; Denholt CS; Thune JJ; Raja AA; Fosbøl E; Schou M; Køber L; Nielsen OW; Gustafsson F; Kristensen SL
    Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):546-552. PubMed ID: 37355774
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
    Pei H; Wang W; Zhao D; Wang L; Su GH; Zhao Z
    Medicine (Baltimore); 2018 Apr; 97(16):e0254. PubMed ID: 29668577
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real world comparison of spironolactone and eplerenone in patients with heart failure.
    Pardo-Martínez P; Barge-Caballero E; Bouzas-Mosquera A; Barge-Caballero G; Couto-Mallón D; Paniagua-Martín MJ; Sagastagoitia-Fornie M; Prada-Delgado Ó; Muñiz J; Almenar-Bonet L; Vázquez-Rodríguez JM; Crespo-Leiro MG
    Eur J Intern Med; 2022 Mar; 97():86-94. PubMed ID: 35000806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
    DE Vecchis R; Ariano C
    Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms: an analysis of the EMPHASIS-HF study.
    Chin KL; Collier TJ; Pitt B; McMurray JJ; Swedberg K; van Veldhuisen DJ; Pocock SJ; Vincent J; Turgonyi E; Zannad F; Krum H;
    Eur J Heart Fail; 2016 Sep; 18(9):1175-81. PubMed ID: 26833642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex differences in mineralocorticoid receptor antagonist trials: a pooled analysis of three large clinical trials.
    Rossello X; Ferreira JP; Pocock SJ; McMurray JJV; Solomon SD; Lam CSP; Girerd N; Pitt B; Rossignol P; Zannad F
    Eur J Heart Fail; 2020 May; 22(5):834-844. PubMed ID: 32077220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS-HF trial.
    Vaduganathan M; Claggett BL; Lam CSP; Pitt B; Senni M; Shah SJ; Voors AA; Zannad F; Desai AS; Jhund PS; Viswanathan P; Bomfim Wirtz A; Schloemer P; Lay-Flurrie J; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2024 Jun; 26(6):1324-1333. PubMed ID: 38742248
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
    Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs.
    Ferreira JP; Pitt B; McMurray JJV; Pocock SJ; Solomon SD; Pfeffer MA; Zannad F; Rossignol P
    JACC Heart Fail; 2022 Nov; 10(11):842-850. PubMed ID: 36328653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.
    Hu LJ; Chen YQ; Deng SB; Du JL; She Q
    Br J Clin Pharmacol; 2013 May; 75(5):1202-12. PubMed ID: 23088367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review.
    Mares A; Rodriguez T; Deoker A; Lehker A; Mukherjee D
    Curr Vasc Pharmacol; 2022; 20(1):46-51. PubMed ID: 34303331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
    Young MJ; Kanki M; Karthigan N; Konstandopoulos P
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
    Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
    Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D
    Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis of clinical trials.
    Oraii A; Healey JS; Kowalik K; Pandey AK; Benz AP; Wong JA; Conen D; McIntyre WF
    Eur Heart J; 2024 Mar; 45(10):756-774. PubMed ID: 38195054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials.
    Rossello X; Ariti C; Pocock SJ; Ferreira JP; Girerd N; McMurray JJV; Van Veldhuisen DJ; Pitt B; Zannad F
    Clin Res Cardiol; 2019 May; 108(5):477-486. PubMed ID: 30264282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Rossignol P; Dobre D; McMurray JJ; Swedberg K; Krum H; van Veldhuisen DJ; Shi H; Messig M; Vincent J; Girerd N; Bakris G; Pitt B; Zannad F
    Circ Heart Fail; 2014 Jan; 7(1):51-8. PubMed ID: 24297687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
    Liu T; Korantzopoulos P; Shao Q; Zhang Z; Letsas KP; Li G
    Europace; 2016 May; 18(5):672-8. PubMed ID: 26705563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.